Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Reaffirmed as “Neutral” by Piper Sandler

Posted by Francis Steltz on Nov 7th, 2026

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities researchers at Piper Sandler in a research note issued to investors on Thursday, Benzinga reports. They currently have a $3.00 target price on the biotechnology company’s stock, up from their previous target price of $2.00. Piper Sandler‘s target price would suggest a potential upside of 32.74% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. UBS Group initiated coverage on shares of Pacific Biosciences of California in a research report on Wednesday, September 9th. They set a “neutral” rating and a $1.35 price target for the company. Wall Street Zen cut Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings raised Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 13th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $2.09.

Read Our Latest Analysis on Pacific Biosciences of California

Pacific Biosciences of California Price Performance

NASDAQ PACB traded down $0.17 during mid-day trading on Thursday, hitting $2.26. The company’s stock had a trading volume of 9,531,021 shares, compared to its average volume of 15,198,901. The firm has a market capitalization of $702.48 million, a P/E ratio of -5.38 and a beta of 2.21. Pacific Biosciences of California has a 52-week low of $1.07 and a 52-week high of $3.43. The stock’s fifty day simple moving average is $1.93 and its two-hundred day simple moving average is $1.62.

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%. The company had revenue of $40.56 million during the quarter, compared to the consensus estimate of $39.31 million. On average, equities analysts forecast that Pacific Biosciences of California will post -0.52 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider James Gibson, II sold 661,815 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total transaction of $2,058,244.65. Following the transaction, the insider directly owned 1,083,848 shares of the company’s stock, valued at approximately $3,370,767.28. The trade was a 37.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the transaction, the insider owned 2,705,853 shares of the company’s stock, valued at $3,057,613.89. This trade represents a 0.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Pacific Biosciences of California

Institutional investors have recently added to or reduced their stakes in the company. Carret Asset Management LLC increased its position in shares of Pacific Biosciences of California by 1.2% during the third quarter. Carret Asset Management LLC now owns 607,140 shares of the biotechnology company’s stock worth $1,439,000 after acquiring an additional 7,000 shares during the last quarter. StoneX Group Inc. purchased a new position in Pacific Biosciences of California in the third quarter valued at about $36,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Pacific Biosciences of California in the third quarter valued at about $38,000. Choreo LLC purchased a new position in Pacific Biosciences of California in the third quarter valued at about $27,000. Finally, Interchange Capital Partners LLC acquired a new stake in Pacific Biosciences of California during the 3rd quarter valued at approximately $28,000.

Pacific Biosciences of California News Roundup

Here are the key news stories impacting Pacific Biosciences of California this week:

Positive Sentiment: PacBio reported third-quarter revenue of $40.56 million, above the $39.31 million consensus, and a loss of $0.11 per share, narrower than the expected $0.13 loss. Coverage also highlighted clinical adoption and AI partnerships as sources of growth. Zacks Q3 results Q3 deep dive
Positive Sentiment: Piper Sandler reaffirmed its Neutral rating but raised its price target to $3 from $2, indicating a more favorable valuation view. Piper Sandler rating
Neutral Sentiment: The company announced CFO changes; the report provided no further detail on the transition’s expected impact. CFO changes
Negative Sentiment: Management narrowed its 2026 revenue guidance to $155 million–$160 million. Analysts also pointed to falling gross margins and substantial cash burn, which raises concerns about the company’s financial position despite its target of cash-flow breakeven in 2028. Revenue guidance and breakeven target Q3 outlook analysis
Negative Sentiment: Barclays lifted its price target to $2 from $1.25 but maintained an Underweight rating, signaling continued caution about the shares. Barclays rating

Pacific Biosciences of California Company Profile

(Get Free Report)

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.